Introduction {#Sec1}
============

Sepsis is a systemic response to infection, which may progress to severe sepsis and septic shock \[[@CR1]\]. Severe sepsis and septic shock represent global problems with a high economic burden. In the United States, more than 750,000 people experience severe sepsis each year, with a short-term mortality of 20% to 30%, reaching up to 50% when shock is present \[[@CR2],[@CR3]\]. Therefore, numerous therapeutic strategies that aimed at reducing mortality in these patients have been investigated. However, most of them have not led to significant reductions in mortality \[[@CR4]\]. Goal-directed therapy (GDT) has been shown to substantially improve clinical outcomes in surgical patients \[[@CR5]\]. Two important aspects of a GDT protocol include early initiation of the therapeutic measures, together with specific (hemodynamic) targets. The Surviving Sepsis Campaign guidelines recommend GDT for the early resuscitation of patients with sepsis \[[@CR1]\], which is based largely upon the results of the Rivers *et al*. trial, in which the researchers reported a 16% absolute reduction in mortality among patients with severe sepsis or septic shock who received early GDT compared to standard therapy \[[@CR6]\]. However, in a recent study, this approach was challenged \[[@CR7]\], with no benefit shown when GDT was compared to standard therapy. However, initiating therapy early rather than late in the course of critical illness remains a logical clinical goal. In the context of this situation, we systematically reviewed all trials of GDT in patients with sepsis and performed a meta-analysis, focusing on the early initiation of the protocol and its effect on mortality.

Methods {#Sec2}
=======

Ethical approval and patient consent were not required, because we conducted a meta-analysis of previously published studies. We followed the recommendations of the *Cochrane Handbook for Systematic Reviews of Interventions* to carry out the study \[[@CR8]\] and follow the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement to report our meta-analysis \[[@CR9]\].

Search strategy {#Sec3}
---------------

Electronic searches were conducted in the PubMed, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) databases. Search terms included "goal directed," "goal oriented," "goal target," "cardiac output," "cardiac index," "oxygen delivery," "oxygen consumption," "cardiac volume," "stroke volume," "fluid therapy," "fluid loading," "fluid administration," "optimization," "optimization," "supranormal" and "sepsis," "severe sepsis," "septic shock," "septicemia," "septicaemia," "pyohemia," "pyaemia" and "pyemia." There was no language restriction placed on the searches. Each database was searched from inception to April 2014. Additionally, reference lists in the articles chosen for inclusion, and the reference lists of previous reviews were screened to identify other potentially eligible trials.

Inclusion criteria {#Sec4}
------------------

We included trials with the following characteristics:*Population*: Adult patients with one or more of the following characteristics were eligible for inclusion: sepsis, severe sepsis or septic shock. *Adults* were defined as being of a legal age for consent in the country where the trial was conducted. Studies that included sepsis secondary to noninfectious causes were excluded.*Intervention*: The intervention had to be *GDT*, defined as an explicit protocol encompassing the use of hemodynamic monitoring and manipulation of hemodynamic parameters to achieve predetermined hemodynamic endpoints.*Control*: The control group had to have received standard therapy or usual care.*Outcomes*: The overall mortality rate had to be the outcome measured.*Type of study*: The studies had to be randomized controlled trials (RCTs).

We included studies that randomized a mixed population of critically ill patients when a septic subpopulation that met our inclusion criteria was defined; that is, the patients with sepsis constituted a subgroup of the trial population.

Data extraction {#Sec5}
---------------

We extracted data using a standardized data collection form. Discrepancies in collected data were addressed through team consensus. The following information was extracted from each trial: first author, year of publication, number of patients (GDT and control), study population, clinical setting, goals in GDT and control groups, timing of GDT, mortality endpoint, study design (patient selection and concealment) and outcome data (overall mortality and dobutamine use).

Outcomes and definitions {#Sec6}
------------------------

The prespecified primary outcome was overall mortality. If the study authors reported mortality at one time point, we used the only data used for analysis. If the study authors reported mortality at more than one time point, we used hospital mortality preferentially. Secondary outcomes included overall mortality in the early-initiated GDT (that is, within the first 6 hours) versus GDT and dobutamine use initiated later.

Assessment of risk of bias {#Sec7}
--------------------------

We used the Cochrane Collaboration tool to assess the risk of bias of individual study and with bias domains across studies \[[@CR8],[@CR10]\]. Two investigators (WJG and FW) subjectively reviewed all studies and assigned a value of "high," "low" or "unclear" to the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. Trials with high risk of bias for any one or more key domains were considered to be at high risk of bias. Trials with low risk of bias for all key domains were considered to be at low risk of bias. Otherwise, they were considered to have an unclear risk of bias \[[@CR10]\].

Statistical analysis {#Sec8}
--------------------

We estimated the relative risk (RR) with 95% confidence interval (CI) for dichotomous outcomes. Statistical heterogeneity across studies was tested by using the *I*^2^ statistic \[[@CR11],[@CR12]\]. Heterogeneity was suggested if the *P*-value was ≤0.10. *I*^2^ values of 0 to 24.9%, 25% to 49.9%, 50% to 74.9% and 75% to 100% were considered zero, low, moderate and high thresholds for statistical heterogeneity, respectively \[[@CR11],[@CR12]\]. Clinical heterogeneity could not be excluded, so the more conservative random-effects model \[[@CR13]\] (Mantel--Haenszel method) was used. Predefined subgroup analysis was conducted according to the timing of GDT for resuscitation (early being within the first 6 hours versus late or unclear being outside the first 6 hours or unclear timing). In addition, we performed *post hoc* subgroup analyses according to risk of bias (low versus unclear), sample size (≥100 versus \<100) and setting (emergency department versus intensive care unit). We further investigated the influence of a single study on the overall pooled estimate by omitting one study in each step. The potential for bias was assessed by inspection of a funnel plot and Egger's test \[[@CR14]\]. The results were considered statistically significant at two-sided *P*-values \<0.05. All statistical analyses were performed using RevMan 5.2 software (The Nordic Cochrane Centre, Copenhagen, Denmark).

Quality of evidence {#Sec9}
-------------------

We evaluated the quality of the evidence by using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach \[[@CR15]\]. In addition, the GRADEprofiler 3.6 software (The Nordic Cochrane Centre) was used to create the evidence profile. The GRADE Working Group grades of evidence used were as follows:*High quality*: Further research is very unlikely to change our confidence in the estimate of effect.*Moderate quality*: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.*Low quality*: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.*Very low quality*: We are very uncertain about the estimate.

Results {#Sec10}
=======

In the initial search, we identified 1,263 records. After examination of the titles and abstracts, there were 30 potentially eligible studies assessed for inclusion. After application of the inclusion criteria, 13 RCTs \[[@CR6],[@CR7],[@CR16]-[@CR26]\] were included in the meta-analysis. The study flow diagram, including the reasons for exclusion of studies, is shown in Figure [1](#Fig1){ref-type="fig"}.Figure 1**Flow diagram showing results of search and reasons for exclusion of studies.** RCT, Randomized controlled trial.

Study characteristics {#Sec11}
---------------------

The characteristics of the included trials are presented in Table [1](#Tab1){ref-type="table"}. These trials were published between 1992 and 2014. The sample size of the trials ranged from 34 to 895, with a total of 2,525 patients comprising 1,299 in the GDT group and 1,226 in the control group. Eleven trials were conducted in the intensive care unit \[[@CR16]-[@CR26]\], and the remaining two were conducted in the emergency department \[[@CR6],[@CR7]\]. Four trials were published in Chinese \[[@CR23]-[@CR26]\], and the other nine trials were in English \[[@CR6],[@CR7],[@CR16]-[@CR22]\]. Early GDT for resuscitation within the first 6 hours was reported in seven trials \[[@CR6],[@CR7],[@CR16],[@CR21],[@CR22],[@CR24]-[@CR26]\], late GDT for resuscitation outside the first 6 hours was assessed in one trial \[[@CR23]\] and unclear timing of GDT was described in five trials \[[@CR17]-[@CR21]\]. Overall mortality was reported in all trials \[[@CR6],[@CR7],[@CR16]-[@CR26]\], and dobutamine use was described in eight of them \[[@CR6],[@CR7],[@CR16]-[@CR19],[@CR21],[@CR22]\].Table 1**Characteristics of included randomized controlled trials** ^**a**^**StudyYearNo. of patients with sepsis (GDT/control)Study populationClinical settingGoals in GDT groupGoals in control groupTiming of GDTMortality endpoint**Tuchschmidt *et al*. \[[@CR16]\]199251 (26/25)Adult patients with septic shockICUCI ≥6 L/min/m^2^CI ≥3 L/min/m^2^Within the first 6 hr14 daysSBP ≥90 mmHgSBP ≥90 mmHgYu *et al*. \[[@CR17]\]199352 (30/22)Adult patients with sepsis or septic shockICUDO~2~I \>600 ml/min/m^2^DO~2~I 450 to 550 ml/min/m^2^Unclear30 days(septic subpopulation)SBP \>100 mmHgSBP \>100 mmHgHayes *et al*. \[[@CR18]\]199447 (24/23)Adult patients with septic shockICUCI ≥4.5 L/min/m^2^Usual careUnclearHospital(septic subpopulation)DO~2~ 600 ml/min/m^2^VO~2~ \> 170 ml/min/m^2^Gattinoni *et al*. \[[@CR19]\]1995181 (124/57)Adult patients with septic shock or septic syndromeICUCI ≥4.5 L/min/m^2^ or SvO~2~ ≥ 70%CI 2.5 to 3.5 L/min/m^2^UnclearICUMAP ≥65 mmHg(septic subpopulation)MAP ≥65 mmHgCVP 8 to 12 mmHgCVP 8 to 12 mmHgUO ≥0.5 ml/kg/hrUO ≥0.5 ml/kg/hYu *et al*. \[[@CR20]\]199887 (58/29)Adult patients with sepsis, severe sepsis or septic shockICUDO~2~I \>600 ml/min/m^2^DO~2~I 450 to 550 ml/min/m^2^UnclearICUSBP ≥100 mmHgSBP ≥100 mmHg(septic subpopulation)SvO~2~ \> 65%SvO~2~ \> 65%UO \>50 ml/hrUO \>50 ml/hrAlía *et al*. \[[@CR21]\]199963 (31/32)Adult patients with severe sepsis or septic shockICUDO~2~I \>600 ml/min/m^2^DO~2~I \>330 ml/min/m^2^UnclearICUMAP \>60 mmHgMAP \>60 mmHgRivers *et al*. \[[@CR6]\]2001263 (130/133)Adult patients with severe sepsis, septic shock or sepsis syndromeEDSvO~2~ ≥ 70%CVP 8 to 12 mmHgWithin the first 6 hrHospitalCVP 8 to 12 mmHgMAP 65 to 90 mmHgMAP 65 to 90 mmHgUO ≥0.5 ml/kg/hrUO ≥0.5 ml/kg/hrLin *et al*. \[[@CR22]\]2006224 (108/116)Adult patients with septic shockICUCVP 8 to 12 mmHgUsual careWithin the first 6 hrHospitalMAP ≥65 mmHgUO ≥0.5 ml/kg/hrWang *et al*. \[[@CR23]\]200634 (16/17)Adult patients with septic shockICUSvO~2~ ≥ 70%MAP ≥65 mmHgWithin the first 6 to 10 hr14 daysCVP 8 to 12 mmHgUO ≥0.5 ml/kg/hrMAP ≥65 mmHgUO ≥0.5 ml/kg/hrChen *et al*. \[[@CR24]\]2007123 (58/65)Adult patients with severe sepsisICUScvO~2~ ≥ 70%CVP 8 to 12 mmHgWithin the first 6 hrICU(septic subpopulation)CVP 8 to 12 mmHgMAP ≥65 mmHgMAP ≥65 mmHgUO ≥0.5 ml/kg/hrUO ≥0.5 ml/kg/hrHe *et al*. \[[@CR25]\]2007203 (98/105)Adult patients with septic shockICUScvO~2~ or SvO~2~ ≥ 70%Usual careWithin the first 6 hrHospitalCVP 8 to 12 mmHgMAP ≥65 mmHgUO ≥0.5 ml/kg/hrYan *et al*. \[[@CR26]\]2010303 (157/146)Adult patients with severe sepsis or septic shockICUScvO~2~ ≥ 70%CVP 8 to 12 mmHgWithin the first 6 hrICUCVP 8 to 12 mmHgSBP \>90 mmHgSBP \>90 mmHgMAP ≥65 mmHgMAP ≥65 mmHgUO ≥0.5 ml/kg/hrUO ≥0.5 ml/kg/hrProCESS \[[@CR7]\]2014895 (439/456)Adult patients with septic shockEDScvO~2~ ≥ 70%Usual careWithin the first 6 hrHospitalCVP 8 to 12 mmHgMAP 65 to 90 mmHgUO ≥0.5 ml/kg/hr^a^CI, Cardiac index; CVP, Central venous pressure; DO~2~, Oxygen delivery; DO~2~I, Oxygen delivery index; ED, Emergency department; GDT, Goal-directed therapy; ICU, Intensive care unit; MAP, Mean arterial pressure; ProCESS, Protocolized Care for Early Septic Shock; SIRS, Systemic inflammatory response syndrome; SBP, Systolic blood pressure; ScvO~2~, Central venous oxygen saturation; SvO~2~, Mixed venous oxygen saturation; UO, Urine output; VO~2~, Oxygen consumption.

Risk of bias in included studies {#Sec12}
--------------------------------

The details of risk of bias are summarized in Figure [2](#Fig2){ref-type="fig"}. Five trials were judged to be at low risk of bias \[[@CR6],[@CR7],[@CR19],[@CR21],[@CR22]\], and eight trials were judged to be at unclear risk of bias \[[@CR16]-[@CR18],[@CR20],[@CR23]-[@CR26]\]. Adequate randomized sequences were generated in eight trials \[[@CR6],[@CR7],[@CR17]-[@CR19],[@CR21],[@CR22],[@CR26]\], and the investigators in five trials reported appropriate allocation concealment \[[@CR6],[@CR7],[@CR19],[@CR21],[@CR22]\]. Among the 13 RCTs, none were double-blinded. However, blinding of patients and clinicians was extremely difficult in these trials to evaluate a complex intervention such as a GDT protocol, and we judged that the primary outcome (that is, overall mortality) was not likely to be influenced by lack of blinding.Figure 2**Risk of bias summary.**

Primary outcome: overall mortality {#Sec13}
----------------------------------

Mortality data were available in all 13 included trials \[[@CR6],[@CR7],[@CR16]-[@CR26]\]. The overall mortality data in the GDT and control groups were 474 (36.5%) of 1,299 and 520 (42.4%) of 1,226, respectively. Overall, GDT significantly reduced overall mortality in the random-effects model (RR, 0.83; 95% CI, 0.71 to 0.96; *P* =0.01; *I*^2^ = 56%) (Figure [3](#Fig3){ref-type="fig"}). Further exclusion of any single study did not alter the overall combined RR, which ranged from 0.80 (95% CI, 0.69 to 0.93) to 0.85 (95% CI, 0.73 to 0.98). The results of subgroup analyses are presented in Table [2](#Tab2){ref-type="table"}.Figure 3**Forest plot of the effect goal-directed therapy on overall mortality.** GDT, Goal-directed therapy.Table 2**Subgroup analyses of overall mortality** ^**a**^**SubgroupsNo. of studiesNo. of patientsRR (95% CI)*P***-**value*I*** ^**2**^ **(%)**All trials \[[@CR6],[@CR7],[@CR16]-[@CR26]\]132,5250.83 (0.71 to 0.96)0.0156GDT timing Early \[[@CR6],[@CR7],[@CR16],[@CR22],[@CR24]-[@CR26]\]72,0620.77 (0.67 to 0.89)0.000440 Late or unclear \[[@CR17]-[@CR21],[@CR23]\]64630.92 (0.69 to 1.24)0.5956Risk of bias Low \[[@CR6],[@CR7],[@CR19],[@CR21],[@CR22]\]51,6260.92 (0.75 to 1.13)0.4267 Unclear \[[@CR16]-[@CR18],[@CR20],[@CR23]-[@CR26]\]88990.74 (0.62 to 0.89)0.00231Sample size ≥100 \[[@CR6],[@CR7],[@CR19],[@CR22],[@CR24]-[@CR26]\]72,1920.82 (0.70 to 0.95)0.0159 \<100 \[[@CR16]-[@CR18],[@CR20],[@CR21],[@CR23]\]63330.81 (0.56 to 1.17)0.2761Setting ED \[[@CR6],[@CR7]\]21,1580.86 (0.52 to 1.44)0.5283 ICU \[[@CR16]-[@CR26]\]111,3670.81 (0.69 to 0.96)0.0153^a^CI, Confidence interval; ED, Emergency department; GDT, Goal-directed therapy; ICU, Intensive care medicine; RR, Relative risk.

Secondary outcomes {#Sec14}
------------------

Predefined subgroup analysis according to the timing of GDT for resuscitation suggested that a mortality benefit was seen only in the subgroup in early GDT within the first 6 hours (seven trials; RR, 0.77; 95% CI, 0.67 to 0.89; *P* =0.0004; *I*^2^ = 40%) (Figure [4](#Fig4){ref-type="fig"}), but not in the subgroup with late or unclear timing of GDT (six trials; RR, 0.92; 95% CI, 0.69 to 1.24; *P* =0.59; *I*^2^ = 56%) (Figure [4](#Fig4){ref-type="fig"}).Figure 4**Forest plot of the effect goal-directed therapy on overall mortality according to the timing of treatment.** GDT, Goal-directed therapy.

In five trials, the investigators reported available data on dobutamine use \[[@CR6],[@CR7],[@CR16],[@CR21],[@CR22]\]. In those trials, GDT was significantly associated with dobutamine use (RR, 2.71; 95% CI, 1.20 to 6.10; *P* =0.02; *I*^2^ = 86%).

Publication bias {#Sec15}
----------------

We detected no evidence of publication bias by assessing funnel plot either visually (Figure [5](#Fig5){ref-type="fig"}) or statistically (*P* =0.367 by Egger test).Figure 5**Funnel plot of the effect goal-directed therapy on overall mortality.** GDT, Goal-directed therapy.

GRADE profile evidence {#Sec16}
----------------------

We found that GRADE Working Group grades of evidence were low for overall mortality, moderate for mortality in early GDT (within the first 6 hours for resuscitation) and very low for dobutamine use. An additional .doc file shows these data in more detail (see Additional file [1](#MOESM1){ref-type="media"}).

Discussion {#Sec17}
==========

Our meta-analysis of 13 RCTs showed that GDT was associated with a 17% RR reduction on overall mortality in patients with sepsis. This mortality benefit was present in studies in which GDT was started early, but not when initiated late or when the timing of GDT was unclear. In addition, GDT was significantly associated with dobutamine use.

Despite these findings, the effect of GDT remains a matter of debate, as the most recent and largest trial included in this meta-analysis \[[@CR7]\] did not show a difference in mortality, in contrast to many of the preceding studies. This could be due to the effect of the rapid acceptance of the principal interventions of the Rivers *et al*. study \[[@CR6]\] and the subsequent Surviving Sepsis Campaign guidelines, which encompassed all elements of the Rivers study protocol. This is illustrated by the fact that, in the ProCESS (Protocolized Care for Early Septic Shock) trial, all groups received, on average, more than 2 L of fluid prior to randomization and more than 75% of patients received antibiotics before randomization. In addition, the mortality rate was much lower in the ProCESS trial than in preceding trials, possibly reflecting the effect of early diagnosis, fluid resuscitation and initiation of antibiotics on mortality. As the ProCESS trial, like the Rivers *et al*. study, enrolled patients with sepsis in the emergency department, this effect may have been prominent \[[@CR27]\].

Although the current evidence supports the early use of GDT to improve outcomes in patients with sepsis, the optimal goals remain uncertain. Currently, the Surviving Sepsis Campaign guidelines recommend the use of central venous pressure (CVP), mean arterial pressure, urine output and central venous oxygen saturation (ScvO~2~) as resuscitation goals. However, many of these recommendations have been questioned in recent studies. A recent study \[[@CR28]\] was designed to compare the use of lactate clearance to ScvO~2~ as a goal of early (up to 6 hours) sepsis resuscitation. No significant difference in mortality was found (17% in the lactate clearance group versus 23% in ScvO~2~ group). However, when both normalization of ScvO~2~ and a rapid decrease in lactate levels were applied as therapeutic goals in the early resuscitation of a mixed group of critically ill patients, including a large subgroup of sepsis patients, mortality was significantly reduced \[[@CR29]\]. In addition, in a recent retrospective study, researchers questioned the CVP endpoint in sepsis resuscitation \[[@CR30]\].

Further research is needed before strong and definitive recommendations can be made regarding the effect of GDT for resuscitation of patients with sepsis. There are currently at least two ongoing RCTs of GDT in patients with sepsis: the Australasian Resuscitation in Sepsis Evaluation (ARISE) trial in Australia (ClinicalTrials.gov ID: NCT00975793) and the Protocolised Management in Sepsis (ProMISe) trial in the United Kingdom (Current Controlled Trials number: ISRCTN36307479) \[[@CR31]\]. The results of these ongoing trials should provide further guidance as to the effect of GDT for resuscitation of patients with sepsis.

A major strength of the present meta-analysis is its compliance with the Cochrane handbook methodology recommendations. We conducted an exhaustive literature search that included non-English-language articles. Two authors independently screened all references, included eligible trials, extracted data information, assessed risk of bias and performed statistical analyses. Moreover, we followed the PRISMA statement to report this meta-analysis and evaluated the quality of the evidence by using the GRADE approach.

Because early fluid resuscitation is vital in patients with sepsis, we performed predefined subgroup analyses according to the timing of GDT. We also performed *post hoc* subgroup analyses according to risk of bias, disease severity, sample size and publication date. These subgroup analyses based on assessment of bias and clinically relevant groups may help health care professionals in clinical decision-making.

Our analysis also has several limitations that must be taken into consideration when interpreting the results. First, most of the included trials had a high risk of bias (Figure [2](#Fig2){ref-type="fig"}). The potential importance of this issue is highlighted by the fact that predefined subgroup analysis comparing mortality estimates between trials with low versus unclear risk of bias suggested the mortality benefit is not clearly apparent among the trials with low risk of bias, although this subgroup difference was not statistically significant (*P* =0.90). Second, there were some differences in the target populations and protocols of GDT of each study. These factors may have a potential impact on our results and may preclude firm conclusions. Third, different endpoints were used for mortality evaluation. Because this study was a study-level meta-analysis, individual patient data were not included in the analysis; thus, we could not adjust for patient-level confounders.

Conclusions {#Sec18}
===========

The evidence suggests that GDT significantly reduces overall mortality in patients with sepsis, especially when initiated early (within the first 6 hours of admission). Until the results of ongoing randomized controlled trials are known, strong and definitive recommendations cannot be made regarding the effect of GDT for resuscitation of patients with sepsis.

Key messages {#Sec19}
============

The Surviving Sepsis Campaign guidelines recommend GDT for the early resuscitation of patients with sepsis, but controversies about its effect remain.The recent ProCESS trial has shown no mortality benefit from GDT in early septic shock.The current evidence, in the aggregate, suggests that GDT significantly reduces overall mortality in patients with sepsis, especially when initiated early (within the first 6 hours of admission).Further research is needed before strong and definitive recommendations can be made regarding the effect of GDT for resuscitation of patients with sepsis, and the optimal goals remain uncertain.

Additional file {#Sec20}
===============

Additional file 1:**GRADE summary of findings.**
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